Physician profile
Hailey Richter
NPI 1841964202
$11,155.35
in general payments reported to CMS, 2019-2025
23 companies · $3,760 in 2025
The $3,760 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,111 · 2023: $2,377 · 2024: $3,906 · 2025: $3,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,956 · Education: $88.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,955.80 |
| Education | $88.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,894.26 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $1,656.85 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,164.58 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,087.22 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $797.67 | 2022-2025 | Auvelity |
| Alkermes, INC. | $779.44 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Tris Pharma INC | $605.98 | 2023-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $473.37 | 2022-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $434.40 | 2023-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $432.54 | 2022-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $431.89 | 2022-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $330.52 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $216.46 | 2022-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $190.21 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $183.41 | 2024-2025 | Cobenfy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $135.31 | 2024-2025 | Xelstrym, Secuado |
| Corium, LLC | $113.35 | 2023-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $89.17 | 2023-2025 | Quviviq, Quviviq |
| Neurocrine Biosciences, INC. | $57.85 | 2025 | |
| Biogen, INC. | $22.80 | 2025 | Zurzuvae |
| Novo Nordisk INC | $22.74 | 2024 | Wegovy |
| Eisai INC. | $20.17 | 2025 | |
| Tempus Ai, INC | $15.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailey Richter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.